
==== Front
Asian Pac J Cancer Prev
Asian Pac J Cancer Prev
APJCP
Asian Pacific Journal of Cancer Prevention : APJCP
1513-7368
2476-762X
West Asia Organization for Cancer Prevention Iran

38918652
10.31557/APJCP.2024.25.6.1921
Review Article
Neutrophil to Lymphocyte Ratio and Platelet to Lymphocyte Ratio as an Early Prognostic Marker in Patients with Ovarian Cancer: A Systematic Review and Meta-Analysis
Winata I Gde Sastra 1*
Pradnyana I Wayan Agus Surya 2
Yusrika Mirani Ulfa 2
Pradnyaandara I Gusti Bagus Mulia Agung 2
Pradnyadevi Putu Agung Satvika 2
1 Gynecology Oncology Division, Department of Obstetrics and Gynaecology Faculty of Medicine, Udayana University, Denpasar, Bali, Indonesia.
2 School of Medicine, Faculty of Medicine, Udayana University, Bali, Indonesia.
* For Correspondence: sastra@unud.ac.id
2024
25 6 19211927
https://creativecommons.org/licenses/by-nc/4.0/ This work is licensed under a Creative Commons Attribution-Non Commercial 4.0 International License. https://creativecommons.org/licenses/by-nc/4.0/
Objective:

Presently, ovarian cancer remains the leading cause of death in gynecological malignancies. The survival rate of these patients is low, which might be caused by early metastases and delayed diagnosis. Therefore, it is crucial to investigate novel practical markers that provide early prognostic value which helps construct individualized treatment.

Methods:

A thorough investigation of the neutrophil-lymphocyte ratio (NLR) and lymphocyte ratio (PLR) in ovarian cancer patients was conducted using article selection from PubMed, Cochrane, Science Direct, and Google Scholar databases. The outcomes and hazard ratio (HR) were obtained using Review Manager 5.4, and the 95% Confidence Interval (CI) result was calculated. The chief endpoints of interest in this study include overall survival (OS) and progression-free survival (PFS).

Results:

Sixteen studies with 3,862 patients were included with a mean age of 50.6 years and a mean follow-up of 45.84 months. Multivariate studies demonstrated that a higher NLR is associated with worse PFS and OS, HR 1.35;95% CI [1.05–1.74] and HR 1.46; 95% CI [1.16–1.83] respectively. Similar results are observed with PLR and poorer PFS and OS, HR 1.62; 95% CI [1.09–2.43] and HR 1.66; 95% CI [1.12–2.46].

Conclusion:

Pre-treatment PLR and NLR were found to be prognostic factors in determining PFS and OS in ovarian cancer. High values in pre-treatment PLR and NLR may indicate worse clinical outcomes.

Key Words

Cervical cancer
neutrophil
lymphocyte
platelet
prognostic
==== Body
pmcIntroduction

Cancer is a highly debilitating disease and accounts for a sizable number of mortalities worldwide. In women, ovarian cancer is one of the most common types reported with approximately 200,000 new cases of ovarian cancer diagnosed annually. This number is expected to increase to 371,000 new cases yearly by 2035, which is a major cause for concern [1-2]. Ovarian cancer has a high mortality rate of 6.3 per 100,000 women every year, making it one of the deadliest and most challenging cancers to treat [3-4]. It is often called the “silent killer” because patients commonly show no symptoms until it reaches an advanced stage [5-6]. However, when patients do exhibit symptoms, primary care providers often fail to notice them [7].

Ovarian cancer alone has a 5-year survival rate of <50%, it’s worth noting that the majority of ovarian cancers, roughly 80%, are detected in the later stages of the disease when it has spread beyond the ovaries [8-10]. Thus, earlier diagnosis is exceptionally crucial in ovarian cancer patients, with the help of standard parameters to help clinicians identify the disease and start individualized treatment earlier.

Several studies have demonstrated systemic inflammatory activation induced by these cancer cells that anticipates tumor development by causing cancer multiplication and metastasis or facilitating angiogenesis. This inflammatory response is closely related to cancer initiation, development, and metastasis [11-12]. Therefore, we systematically searched scientific data on inflammatory markers such as the neutrophil-lymphocyte ratio (NLR) and lymphocyte-platelet ratio (PLR), to explore their association with overall survival (OS) and progression-free survival (PFS) of ovarian cancer patients. NLR and PLR might prove to be a valuable prognostic marker, given that these markers are widely available in clinical practice.

Materials and Methods

This study performed a systematic review and meta-analysis while adhering to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The research utilized data from previously published studies, therefore ethical approval was not necessary. The study’s protocol has been registered with the CRD number 42024500275 on the International Prospective Register of Systematic Reviews (PROSPERO) (www.crd.york.ac.uk/prospero).

Search Strategy

According to Medical Literature Analysis and Retrieval System Online (MEDLINE), a systematic research on PubMed, Cochrane Library, Science Direct, and Google Scholar databases from 2002-2023 was conducted using the terms: “Ovarian Neoplasm OR Ovarian Cancer OR Ovary Cancer OR Ovary Neoplasm”, ”Platelets lymphocyte ratio OR platelet to lymphocyte ratio OR PLR”, “Neutrophil lymphocyte ratio OR Neutrophil to lymphocyte ratio OR NLR”, “Prognosis OR Outcome”, in English and full-text publication. We performed an additional manual search by reviewing the references of all included and appropriate studies later. The conclusive research inquiry pertains to the potential association between the Neutrophil-to-Lymphocyte Ratio (NLR) and/or the Platelet-to-Lymphocyte Ratio (PLR) in the context of ovarian cancer or ovarian neoplasm as a predictive marker.

Inclusion Criteria

To ensure the selected study is comprehensive and relevant, it must meet several specific criterias. These include: (1) being a retrospective or prospective study with full-text available; (2) examining the significance of pre-treatment NLR and/or PLR parameter as a prognostic marker for ovarian cancer; (3) providing hazard ratios (HR) or provided sufficient information in calculating HR for either progression-free survival (PFS) or overall survival (OS), as well as their corresponding 95% confidence intervals (CIs) or p-values; (4) the study reported the cut-off value of NLR and PLR; and (5) being published in the English language.

Data Extraction and Quality Assessment

Standardized forms were used during data extraction and quality assessment by three researchers. Each study extracted information includes the authors, design and methodology, total and mean patient age, NLR and PLR values, progression-free survival values, and Overall Survival values for each NLR or PLR group compared to the control group. In instances of unclear or missing data in the primary results, the original publication authors were contacted via email for clarification.

Modified Newcastle-Ottawa Scale is used to analyze the risk of bias for Cohort Studies [13]. The scale comprises eight items that are categorized into three domains. The outcome domain carries three points, while the comparability domain is worth two points. There are four total points for domain selection. The study quality was deemed “good” if the total score was between 7-9, “moderate” for scores between 4-6, and anything below that was considered “poor.” Additionally, the three reviewers took the risk bias assessment independently with any disputes settled through dialogues with the fourth reviewer. The prevailing quality of the non-comparative studies was sufficient, with an average score of 7.7 points.

Data Synthesis and Analysis Quality Assessment

We utilized Review Manager 5.4 to analyze the data gathered in this study. Our findings will be presented as hazard ratios (HRs) with 95% confidence intervals (CIs). To assess heterogeneity between study populations, we employed the I2 statistic. This metric categorizes results as follows: no heterogeneity (0-24%), moderate heterogeneity (25%-49%), considerable heterogeneity (50-74%), and extreme heterogeneity (75%-100%). To summarize data across groups, we used the Mantel-Haenszel (M-H) method for hazard ratio (HR). We applied a fixed effect model if I2 was less than 25%. Random effect model will be used if I2 transcended 25% [14]. Moreover, to assess publication bias, we employed funnel plots. Our analysis was conducted using Review Manager 5.4.

Results

Literature Search

Our initial search found 1,255 studies from highly regarded sources like Cochrane, Science Direct, PubMed, and Google Scholar. After carefully sifting through these studies and eliminating duplicates, we assessed the titles and abstracts of 1,067 studies against specific criteria. Of these, we excluded many based on our inclusion criteria, leaving us with 184 observational studies for further review. Unfortunately, 168 of these studies did not meet our parameters and were excluded. Only 16 final eligible studies, mostly were retrospective observational studies, and was conducted in Asians [10,11, 15-28]. A total of 3,862 patients, with 2,793 Asian patients, were included in the systematic review and meta-analysis. The mean age was 50.6 years old, with a mean follow-up of 45.8 months. Moreover, cut-off lab parameters were 209.78 for PLR and 3.24 for NLR. The flow diagram of the study selection process is provided in Figure 1.

Progression Free Survival

Pooled univariate studies of ovarian cancer patients showed that higher pre-treatment NLR values are associated with worse PFS (HR 1.76; 95% CI [0.99–3.13], I2=93%). The forest plot shows that from the six studies analyzed, only two had no notable difference between the two groups, and the difference was only marginal. Interestingly, when we further analyzed the multivariate studies, higher NLR had remarkably worse PFS (HR 1.35; 95% CI [1.05-1.74], I2=74%). Figure 2 shows the forest plot of PFS for the NLR parameter.

Six univariate studies were reported for the correlative value between PLR and PFS in patients with ovarian cancer. The forest plot demonstrated that higher PLR is significantly linked to poorer PFS (HR 2.20; 95% CI [1.56–3.09], I2=73%). Furthermore, the forest plot of the multivariate studies showed a similar result: patients with high PLR have significantly worse PFS (HR 1.62, 95% CI [1.09–2.43], I2=87%). Figure 3 provides the forest plot of PFS for the PLR parameter.

Overall Survival

This analysis includes eight univariate studies of NLR on OS in ovarian cancer patients. The forest plot reveals a correlative value between higher NLR and worsening OS (HR 2.49; 95% CI [1.42-4.35], I2=90%). Only one study reported an insignificant difference between the two groups. Nine multivariate studies were included for pooled multivariate analysis and showed analogous results (HR 1.46; 95% CI [1.16-1.83], I2=63%).

Analysis for PLR includes seven univariate studies and seven multivariate studies. Higher PLR correlates with worse OS both in the analysis of univariate and multivariate studies (HR 2.47; 95% CI [1.86–3.26], I2=61% and HR 1.66; 95% CI [1.12–2.46], I2=88%) respectively.

Figure 1 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Flow Diagram

Figure 2 Forest Plot of Univariate Studies (A) and Multivariate Studies (B) of NLR on PFS in Patients with Ovarian Cancer. Note: SE, (Standard Error); IV, (Inverse Variance); CI, (Confidence Interval); NLR, (Neutrophil to lymphocyte Ratio); PFS, (Progression Free Survival)

Figure 3 Forest Plot of Univariate Studies (A) and Multivariate Studies (B) of PLR on PFS in Patients with Ovarian Cancer. Note: SE, (Standard Error); IV, (Inverse Variance); CI, (Confidence Interval); NLR, (Neutrophil to lymphocyte Ratio); PFS, (Progression Free Survival)

Discussion

Many prognostic parameters have been studied to improve the treatment and outcomes of ovarian cancer patients. Currently, patients rely on conventional tests such as TNM staging, CA125, and CA199. However, these tests have limitations and are often unavailable and expensive in many health facilities, particularly in low to middle-income countries. Additionally, these parameters may not fully represent the true burden of ovarian cancer in patients.

Survival rates for ovarian cancer can vary, even when patients have similar disease stages, tumor subtypes, and receive identical treatments. As a result, there is a critical need for novel prognostic biomarkers that can help accurately predict patient prognosis and identify new therapeutic targets [29-30].

Recent studies suggest a correlation between tumor occurrence and development with the inflammatory response in the body. Various parameters related to inflammation, such as neutrophils, platelets, and lymphocytes, have been observed to play a critical role in tumor growth, invasion, and metastasis [10,11, 15-28]. The complete blood count is one of the most commonly used laboratory test and is widely available at all levels of health facilities. It provides information about the neutrophil count, platelet count, NLR, and PLR. Studies have reported a strong association between inflammation and the immune cells that mediate communication between tumor cells and the tumor microenvironment [31-32]. Inflammatory mediators such as interleukin-1 (IL-1), interleukin-6 (IL-6), vascular endothelial growth factor, and tumor necrosis factor can accumulate in neutrophils. This accumulation may promote the survival and multiplication of cancer cells. Neutrophils can also suppress the cytolytic activity of lymphocytes, natural killer cells, and T-cell proliferation [33-34].

Inversely, lymphocytes act as the main defense against tumor cells, inhibiting tumor cell growth and spread. The increased systemic inflammatory response release inhibitory mediators such as interleukin-10 (IL-10) found in the peritoneal fluid and sera of patients with ovarian cancer. This may contribute to the lymphopenia often observed in patients with ovarian cancer [35-37]. Proportion between neutrophils and lymphocytes, such as NLR, might be a promising novel prognostic factor. In addition, NLR parameter from a complete blood count is readily available in health facilities.

On the other hand, mechanism on on how tumors influence the Platelet to Lymphocyte Ratio (PLR) in ovarian cancer patients is not fully understood. The increase in PLR may be caused by a rise in platelet-dependent systemic inflammatory response and a decrease in lymphocyte-mediated antitumor immune response, which creates a favorable environment for tumor growth. Platelets play a vital role in hemostasis, thrombosis, inflammation, and vascular biology. A study with mouse models reported that tumors can cause thrombocytosis and thrombosis by stimulating IL-6 and hepatic thrombopoietin expression. According to recent studies, cancer patients have a high incidence of platelet-derived venous thromboembolism. Tumor cells activate platelets, which in turn promote accelerated tumor growth, angiogenesis, and metastasis. Once the tumor volume exceeds 1-2 mm3, angiogenesis occurs within the tumor from existing blood vessels. This process provides the necessary oxygen and nutrients to support tumor growth [39].

In this meta-analysis, it was found that patients with high NLR and PLR indeed have a worse prognosis. Among fourteen NLR-specific studies, two reported no significant relationship between an increase in NLR and a worsening prognosis [16, 24]. One study found no significant association between an increase in NLR and a deteriorating prognosis in univariate or multivariate analysis regarding PFS (progression-free survival) and OS (overall survival) [16]. After conducting a pooled analysis using a random effects model, the forest plot demonstrated that, overall, patients with increased NLR did have worse PFS and OS when compared to patients who had lower NLR. Notably, the study utilized a retrospective study design, limiting its ability to account for confounding variables such as smoking or oral contraceptive use that may impact systemic inflammatory response. Although the included studies might be affected by bias due to unmeasured confounding factors, NLR’s prognostic value can still be attributed due to its relationship with inflammation.

It is well known that for various types of cancer, a high NLR indicates an advanced stage, or larger tumors with aggressive behavior. Although data on NLR for ovarian cancer is limited, Cho et al. discovered that prediagnostic NLR levels are more significant than platelet count in predicting both overall and progression-free survival in negative CA 125 cases. They also found that NLR levels were significantly higher in ovarian cancer cases than in other benign gynecologic diseases or healthy controls [23].

PLR is found to be a better predictor of tumor response after primary treatment compared to other factors. This is due to the interaction between tumor cells and platelets, which can promote tumor growth, invasion, and angiogenesis. Additionally, platelets can protect tumor cells from attacks by natural killer cells, leading to increased metastasis. As a result, individuals with ovarian cancer often experience thrombocytosis, which is linked to an inadequate response in solid tumors and lymphocytopenia. This occurs because tumor cells release thrombopoietin cytokines such as interleukin-6. [20].

The NLR and PLR are easily accessible and relatively inexpensive parameters that reflect the host’s immune response. These parameters have been shown to be independent prognostic factors in many cancers [38-39]. In patients with ovarian cancer, NLR and PLR serve as markers of malignancy, but there is still conflicting data regarding their significance. This meta-analysis aims to evaluate whether NLR and PLR are significant prognostic factors in patients with ovarian cancer. Due to the lack of established NLR and PLR cut-off points, the results of this pooled analysis suggest that NLR and PLR may be potential predictive markers of ovarian cancer prognosis.

Limitations

There is significant variation among research studies in both NLR and PLR parameters on PFS and OS in pooled analysis. This could be due to the different characteristics of the studies, such as multiple cut-offs, different races, varying definitions of optimal studies, and other factors. In addition, the studies included are retrospective and have relatively small sample sizes. In attempts to address this, we utilize a random sample model in pooled analysis to better represent the results according to the general population.

In conclusion, in our systematic review and meta-analysis, we found that both high Neutrophil to Lymphocyte Ratio (NLR) and Platelet to Lymphocyte Ratio (PLR) are associated with worse progression-free survival (PFS) and five-year overall survival (OS) of patients with ovarian cancer. Our analysis suggests that NLR/PLR could be utilized as an early prognostic marker for ovarian cancer patients. However, a more extensive study which included a greater number of publications, as well as studies with a prospective design are needed to obtain more conclusive results.

Acknowledgements

General

We appreciate for the support provided by the Obstetrics and Gynecology Department staff at Prof. Dr. I.G.N.G Ngoerah General Hospital in Denpasar, Bali, Indonesia. We also extend our gratitude to the Faculty of Medicine Udayana University, for allowing us to conduct this research and providing us with general support throughout the process.

Ethical Declaration

This study is a systematic review and meta-analysis, therefore ethical clearance is not required.

Data Availability

Data supporting the findings in this study is accessible on the attached supplementary materials. Raw datas are available upon request to the corresponding authors.

Study Registration

The study registered on the International Prospective Register of Systematic Reviews (PROSPERO) with the CRD number 42024500275 (www.crd.york.ac.uk/prospero).

Conflict of Interest

The authors state no conflict of interest.

Author Contribution Statement

Contributions are shared equally, all authors participate in the conceptualization, data collection, data analysis and interpretation, as well as the writing of the manuscript.
==== Refs
References

1 Cho KR Shih Ie M Ovarian cancer Annu Rev Pathol 2009 4 287 313 18842102
2 Quaye L Gayther SA Ramus SJ Di Cioccio RA McGuire V Hogdall E The effects of common genetic variants in oncogenes on ovarian cancer survival Clin Cancer Res 2008 14 18 5833 9 18794094
3 Colombo N Van Gorp T Parma G Amant F Gatta G Sessa C Ovarian cancer Crit Rev Oncol Hematol 2006 60 2 159 79 17018256
4 Gajjar K Ogden G Mujahid MI Razvi K Symptoms and risk factors of ovarian cancer: A survey in primary care ISRN Obstet Gynecol 2012 2012 754197 22957264
5 Hennessy BT Coleman RL Markman M Ovarian cancer Lancet 2009 374 9698 1371 82 19793610
6 Jayson GC Kohn EC Kitchener HC Ledermann JA Ovarian cancer Lancet 2014 384 9951 1376 88 24767708
7 Nersesian S Glazebrook H Toulany J Grantham SR Boudreau JE Naturally killing the silent killer: Nk cell-based immunotherapy for ovarian cancer Front Immunol 2019 10 1782 31456796
8 Stewart C Ralyea C Lockwood S Ovarian cancer: An integrated review Semin Oncol Nurs 2019 35 2 151 6 30867104
9 Chien J Poole EM Ovarian cancer prevention, screening, and early detection: Report from the 11th biennial ovarian cancer research symposium Int J Gynecol Cancer 2017 27 9S Suppl 5 S20 s2 29278600
10 Yoshida K Yoshikawa N Shirakawa A Niimi K Suzuki S Kajiyama H Prognostic value of neutrophil-to-lymphocyte ratio in early-stage ovarian clear-cell carcinoma J Gynecol Oncol 2019 30 6 e85
11 Chon S Lee S Jeong D Lim S Lee K Shin J Elevated platelet lymphocyte ratio is a poor prognostic factor in advanced epithelial ovarian cancer J Gynecol Obstet Hum Reprod 2021 50 6 101849 32619726
12 Hainaut P Plymoth A Targeting the hallmarks of cancer: Towards a rational approach to next-generation cancer therapy Curr Opin Oncol 2013 25 1 50 1 23150341
13 Wells GA Shea B O’Connell D Peterson J Welch V Losos M Tugwell P The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses
14 Higgins JP Thompson SG Deeks JJ Altman DG Measuring inconsistency in meta-analyses BMJ 2003 327 7414 557 60 12958120
15 Miao Y Yan Q Li S Li B Feng Y Neutrophil to lymphocyte ratio and platelet to lymphocyte ratio are predictive of chemotherapeutic response and prognosis in epithelial ovarian cancer patients treated with platinum-based chemotherapy Cancer Biomark 2016 17 1 33 40 27314290
16 Kim HS Choi HY Lee M Suh DH Kim K No JH Systemic inflammatory response markers and ca-125 levels in ovarian clear cell carcinoma: A two center cohort study Cancer Res Treat 2016 48 1 250 8 25761476
17 Feng Z Wen H Bi R Ju X Chen X Yang W Preoperative neutrophil-to-lymphocyte ratio as a predictive and prognostic factor for high-grade serous ovarian cancer PLoS One 2016 11 5 e0156101 27203425
18 Zhang WW Liu KJ Hu GL Liang WJ Preoperative platelet/lymphocyte ratio is a superior prognostic factor compared to other systemic inflammatory response markers in ovarian cancer patients Tumour Biol 2015 36 11 8831 7 26063409
19 Wang Y Liu P Xu Y Zhang W Tong L Guo Z Preoperative neutrophil-to-lymphocyte ratio predicts response to first-line platinum-based chemotherapy and prognosis in serous ovarian cancer Cancer Chemother Pharmacol 2015 75 2 255 62 25428515
20 Williams KA Labidi-Galy SI Terry KL Vitonis AF Welch WR Goodman A Prognostic significance and predictors of the neutrophil-to-lymphocyte ratio in ovarian cancer Gynecol Oncol 2014 132 3 542 50 24462730
21 Raungkaewmanee S Tangjitgamol S Manusirivithaya S Srijaipracharoen S Thavaramara T Platelet to lymphocyte ratio as a prognostic factor for epithelial ovarian cancer J Gynecol Oncol 2012 23 4 265 73 23094130
22 Asher V Lee J Innamaa A Bali A Preoperative platelet lymphocyte ratio as an independent prognostic marker in ovarian cancer Clin Transl Oncol 2011 13 7 499 503 21775277
23 Cho H Hur HW Kim SW Kim SH Kim JH Kim YT Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment Cancer Immunol Immunother 2009 58 1 15 23 18414853
24 Eo WK Chang HJ Kwon SH Koh SB Kim YO Ji YI The lymphocyte-monocyte ratio predicts patient survival and aggressiveness of ovarian cancer J Cancer 2016 7 3 289 96 26918042
25 Kim YJ Lee I Chung YS Nam E Kim S Kim SW Pretreatment neutrophil-to-lymphocyte ratio and its dynamic change during neoadjuvant chemotherapy as poor prognostic factors in advanced ovarian cancer Obstet Gynecol Sci 2018 61 2 227 34 29564313
26 Badora-Rybicka A Nowara E Starzyczny-Słota D Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio before chemotherapy as potential prognostic factors in patients with newly diagnosed epithelial ovarian cancer ESMO Open 2016 1 2 e000039 27843595
27 Supoken A Kleebkaow P Chumworathayi B Luanratanakorn S Kietpeerakool C Elevated preoperative platelet to lymphocyte ratio associated with decreased survival of women with ovarian clear cell carcinoma Asian Pac J Cancer Prev 2014 15 24 10831 6 25605185
28 Kwon BS Jeong DH Byun JM Lee TH Choi KU Song YJ Prognostic value of preoperative lymphocyte-monocyte ratio in patients with ovarian clear cell carcinoma J Cancer 2018 9 7 1127 34 29675093
29 Buergy D Wenz F Groden C Brockmann MA Tumor-platelet interaction in solid tumors Int J Cancer 2012 130 12 2747 60 22261860
30 Menon S Shin S Dy G Advances in cancer immunotherapy in solid tumors Cancers (Basel) 2016 8 12 26771641
31 Faria SS Fernandes PC Jr Silva MJ Lima VC Fontes W Freitas-Junior R The neutrophil-to-lymphocyte ratio: A narrative review Ecancermedicalscience 2016 10 702 28105073
32 Nicolás-Ávila J Adrover JM Hidalgo A Neutrophils in homeostasis, immunity, and cancer Immunity 2017 46 1 15 28 28099862
33 Uribe-Querol E Rosales C Neutrophils in cancer: Two sides of the same coin J Immunol Res 2015 2015 983698 26819959
34 Criscitiello C Esposito A Trapani D Curigliano G Prognostic and predictive value of tumor infiltrating lymphocytes in early breast cancer Cancer Treat Rev 2016 50 205 7 27744144
35 Chen LL Ye F Lü WG Yu Y Chen HZ Xie X Evaluation of immune inhibitory cytokine profiles in epithelial ovarian carcinoma J Obstet Gynaecol Res 2009 35 2 212 8 19335794
36 Fumagalli LA Vinke J Hoff W Ypma E Brivio F Nespoli A Lymphocyte counts independently predict overall survival in advanced cancer patients: A biomarker for il-2 immunotherapy J Immunother 2003 26 5 394 402 12973028
37 Fogar P Sperti C Basso D Sanzari MC Greco E Davoli C Decreased total lymphocyte counts in pancreatic cancer: An index of adverse outcome Pancreas 2006 32 1 22 8 16340740
38 Cohen JG Tran AQ Rimel BJ Cass I Walsh CS Karlan BY Thrombocytosis at secondary cytoreduction for recurrent ovarian cancer predicts suboptimal resection and poor survival Gynecol Oncol 2014 132 3 556 9 24423879
39 Labelle M Begum S Hynes RO Platelets guide the formation of early metastatic niches Proc Natl Acad Sci U S A 2014 111 30 E3053 61 25024172
